Immunohistochemistry (IHC) Market By Product Type (Instruments, Reagents & Kits, Services), By Application (Diagnostic, Research, Others), By End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), by geography, is expected to grow at a constant CAGR forecast till 2027 owing to the rising usage of immunohistochemistry (IHC) technology in clinical diagnosis and advancement in IHC products
The global immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2021, growing at a CAGR of 7.64% during the forecast period from 2022 to 2027, to reach USD 3.98 billion by 2027. The growing demand for immunohistochemistry (IHC) is predominantly attributed to the rising cases of chronic and infectious diseases such as cancer, hepatitis B virus, herpes virus, among others. Moreover, the rise in approval and launch of various technologically advanced IHC products, and growing implementation of automation and machine learning concepts in the field of IHC, and increase in research and development activities, among others are some of the factors responsible for driving the Immunohistochemistry (IHC) market in the upcoming years.
Immunohistochemistry (IHC) Market Dynamics:
The market for immunohistochemistry (IHC) is gaining momentum at present due to the surge in various infectious diseases among the population across the globe. This is because the IHC technique uses specific antibodies to viral, bacterial, fungal, and parasitic antigens in the detection and identification of the causative agents in many infectious diseases. For instance, approximately 3.7 billion people under age 50 (67%) have herpes simplex virus type 1 (HSV-1) infection, and an estimated 491 million people aged 15-49 (13%) have herpes simplex virus type 2 (HSV-2) infection globally as per the World Health Organization (WHO) 2020.
In addition, as per the WHO 2021 estimates, approximately 296 million people were living with chronic hepatitis B infection in the year 2019.
Thus, rising various infectious disorders in the worldwide population would raise the demand for IHC testing thereby contributing to the global IHC market growth.
In addition, the increasing burden of cancer cases worldwide is also anticipated to contribute to the Immunohistochemistry (IHC) market. This is because IHC is widely used for the diagnosis of cancers and specific tumor antigens that are expressed de novo or up-regulated in certain cancers. According to the data published by the GLOBOCAN directory in the year 2020, approximately 19,292,789 new cases of cancer were detected, globally in the same year.
However, certain factors such as the risk of false-positive results and the high cost of the instruments are likely to impede the Immunohistochemistry (IHC) market growth.
Also, the unprecedented COVID-19 outbreak had slowed down the overall immunohistochemistry market. This is due to the temporary halt in manufacturing facilities, reduction in the screening process of various diseases such as cancer, and others due to the impose of lockdown restrictions across the globe. However, the pandemic has also provided opportunities for IHC product manufacturers as they have undertaken initiatives to overcome the challenges posed by this pandemic and shifted their business focus by introducing IHC products for COVID-19 research. For instance, Bio SB, a US-based company has developed and manufactured the CoV-2 recombinant proteins and peptides needed to generate antibodies to identify the virus, receptors, and IL’s by Immunohistochemistry and Immunofluorescence on FFPE biopsies. Moreover, due to the launch of various vaccines and mass vaccination drive the market for IHC is likely to regain normalcy owing to the relaxation in restrictions.
Immunohistochemistry (IHC) Market Segment Analysis:
Immunohistochemistry (IHC) Market By Product Type (Instruments, Reagents & Kits, Services), By Application (Diagnostic, Research, Others), By End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Immunohistochemistry (IHC) product type segment, the reagents & kits segment is anticipated to hold a significant market share during the forthcoming years. This is because of the wide availability of regents and kits products in the market for the specific application. In addition, the kits minimize the chances of errors by eliminating the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample.
Moreover, the IHC kits are widely used in research laboratories due to their compact nature and availability of products in small quantities for carrying research and rising research and development activities across the globe would contribute to the segmental market in the upcoming years.
In addition, approval of reagents and kits in recent years is also expected to augment the segmental market for immunohistochemistry (IHC) market. For instance, on March 06, 2020, Leica Biosystems (Danaher Corporation) received FDA clearance for BOND Ready-to-Use Primary Antibody Progesterone Receptor and Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone (Immunohistochemistry reagents and kits).
Thus, all the above-mentioned factors will contribute to the segment growth in the forthcoming years.
North America is expected to dominate the overall Immunohistochemistry (IHC) Market:
Among all the regions, North America is expected to occupy a major share in the overall Immunohistochemistry (IHC) market during the forecasted period. This domination is owing to the growing cases of infectious disease in the region. Furthermore, the surge in the new cancer cases, the presence of key market players, and their strategic business activities, among others are expected to fuel the overall Immunohistochemistry (IHC) market in the region.
For instance, according to the data published by the GLOBOCAN directory in the year 2020, approximately, 2,281,658 new cases of cancer were reported in the US in the same year.
Moreover, the adoption of technologically advanced IHC products and instruments in the region would also raise the market for IHC in the region.
Furthermore, as per the Government of Canada 2018 report, there were a total of 4,783 cases and 12,477 cases of hepatitis B and hepatitis C respectively in Canada.
Additionally, the approval of various IHC products as companion diagnostic for cancer in the region would also raise the market for immunohistochemistry in the upcoming years.
For instance, in November 2020, FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab. The FDA approved the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer who may be appropriate for treatment with pembrolizumab (Keytruda).
Thus, all the above-mentioned factors are likely to grow the market for IHC in the region during the forecasted period.
Immunohistochemistry (IHC) Market Key Players:
Some of the key market players operating in the Immunohistochemistry (IHC) market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne., Genemed Biotechnologies, Inc., Abcam plc, Becton, Dickinson and Company, Bio SB, Inc., BioGenex., Biocare Medical, LLC., Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories., among others.
Recent Developmental Activities in the Immunohistochemistry (IHC) Market:
• On July 20, 2021, Agilent Technologies Inc.’s PD-L1 IHC 22C3 pharmDx assay was labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.
• On April 23, 2021, Roche received FDA approval for the VENTANA MMR RxDx Panel, the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly).
• On March 18, 2021, Roche launched the DISCOVERY Green HRP kit, the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens.
Key Takeaways from the Immunohistochemistry (IHC) Market Report Study
● Market size analysis for current market size (2021), and market forecast for 5 years (2022-2027)
● The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Immunohistochemistry (IHC) market.
● Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
● Key companies dominating the Global Immunohistochemistry (IHC) Market.
● Various opportunities available for the other competitor in the Immunohistochemistry (IHC) Market space.
● What are the top-performing segments in 2021? How these segments will perform in 2027.
● Which are the top-performing regions and countries in the current market scenario?
● Which are the regions and countries where companies should have concentrated on opportunities for Immunohistochemistry (IHC) market growth in the coming future?
Target Audience who can be benefited from the Immunohistochemistry (IHC) Market Report Study
● Immunohistochemistry (IHC) providers
● Research organizations and consulting companies
● Immunohistochemistry (IHC)-related organization, association, forum, and other alliances
● Government and corporate offices
● Start-up companies, venture capitalists, and private equity firms
● Distributors and Traders in Immunohistochemistry (IHC)
● Various End-users who want to know more about the Immunohistochemistry (IHC) Market and the latest technological developments in the Immunohistochemistry (IHC) market.
Frequently Asked Questions for the Immunohistochemistry (IHC) Market:
1. What is Immunohistochemistry (IHC)?
Immunohistochemistry (IHC) is a technique that uses antibodies to check for certain antigens (markers) in a sample of tissue. The antibodies are usually linked to an enzyme or a fluorescent dye.
2.What is the market for Global Immunohistochemistry (IHC)?
The global Immunohistochemistry (IHC) Market was valued at USD 2.56 billion in 2021, growing at a CAGR of 7.64% during the forecast period from 2022 to 2027 to reach USD 3.98 billion by 2027.
3. What are the drivers for Global Immunohistochemistry (IHC)?
The major factors driving the demand for Immunohistochemistry (IHC) are the rising cases of chronic and infectious diseases such as cancer, hepatitis B virus, herpes virus, among others. Moreover, the rise in approval and launch of various technologically advanced IHC products, and growing implementation of automation and machine learning concepts in the field of IHC, and increase in research and development activities, among others are some of the factors responsible for driving the Immunohistochemistry (IHC) market in the upcoming years.
4. What are the key players operating in Global Immunohistochemistry (IHC)?
Some of the key market players operating in the Immunohistochemistry (IHC) market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne., Genemed Biotechnologies, Inc., Abcam plc, Becton, Dickinson and Company, Bio SB, Inc., BioGenex., Biocare Medical, LLC., Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories., among others.
5. Which region has the highest share in the Immunohistochemistry (IHC) market?
Among all the regions, North America is expected to occupy a major share in the overall Immunohistochemistry (IHC) market during the forecasted period, 2022-2027. This domination is owing to the growing cases of infectious disease in the region. Furthermore, the surge in the new cancer cases, the presence of key market players, and their strategic business activities, among others are expected to fuel the overall Immunohistochemistry (IHC) market in the region.
'
1.Immunohistochemistry (IHC) Market Report Introduction
2.Immunohistochemistry (IHC) Market Executive summary
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking
3. Regulatory Analysis
3.1. The United States
3.2. Europe
3.3. Japan
3.4. China
4. Immunohistochemistry (IHC) Market Key factors analysis
4.1. Immunohistochemistry (IHC) Market Drivers
4.1.1. The rising burden of cancer worldwide
4.1.2. Growing incidence of infectious diseases such as hepatitis B, and others across the globe
4.1.3. Rapid approval and launch of Immunohistochemistry (IHC) products
4.1.4. Technological advancement in the manufacturing of Immunohistochemistry (IHC) products
4.2. Immunohistochemistry (IHC) Market Restraints and Challenges
4.2.1. High cost associated with Immunohistochemistry (IHC) instruments and services
4.2.2. Risk of False-Positive Results
4.3. Immunohistochemistry (IHC) Market Opportunities
4.3.1. Low and middle-income nations have tremendous opportunities for the Immunohistochemistry (IHC) market
4.3.2. Strategic business activities by the global as well as regional manufacturers will provide opportunities in the Immunohistochemistry (IHC) market
5. Immunohistochemistry (IHC) Porter’s Five Forces Analysis
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 Impact Analysis on Immunohistochemistry (IHC) Market
7. Immunohistochemistry (IHC) Market layout
7.1. By Product Type
7.1.1. Instruments
7.1.2. Reagents & Kits
7.1.3. Services
7.2. By Application
7.2.1. Diagnostic
7.2.2. Research
7.2.3. Forensic
7.3. By End-user
7.3.1. Hospitals & Diagnostic Laboratories
7.3.2. Academic & research Institutes
7.3.3. Others
7.4. By Geography
7.5.1 North America
7.4.1.1. North America Immunohistochemistry (IHC) Market, by Product Type
7.4.1.2. North America Immunohistochemistry (IHC) Market, by Application
7.4.1.3. North America Immunohistochemistry (IHC) Market, by End User
7.4.1.4. North America Immunohistochemistry (IHC) Market, by Country
7.4.1.4.1. United States
7.4.1.4.2. Canada
7.4.1.4.3. Mexico
7.4.2. Europe
7.4.2.1. Europe Immunohistochemistry (IHC) Market, by Product Type
7.4.2.2. Europe Immunohistochemistry (IHC) Market, by Application
7.4.2.3. Europe Immunohistochemistry (IHC) Market, by End User
7.4.2.4. Europe Immunohistochemistry (IHC) Market, by Country
7.4.2.4.1. France
7.4.2.4.2. Germany
7.4.2.4.3. United Kingdom
7.4.2.4.4. Italy
7.4.2.4.5. Spain
7.4.2.4.6. Russia
7.4.2.4.7. Rest of Europe
7.4.3. Asia-Pacific
7.4.3.1. Asia-Pacific Immunohistochemistry (IHC) Market, by Product Type
7.4.3.2. Asia-Pacific Immunohistochemistry (IHC) Market, by Application
7.4.3.3. Asia-Pacific Immunohistochemistry (IHC) Market, by End User
7.4.3.4. Asia-Pacific Immunohistochemistry (IHC) Market, by Country
7.4.3.4.1. China
7.4.3.4.2. Japan
7.4.3.4.3. India
7.4.3.4.4. Australia
7.4.3.4.5. South Korea
7.4.3.4.6. Rest of Asia Pacific
7.4.4. Rest of the World (RoW)
7.4.4.1. RoW Immunohistochemistry (IHC) Market, by Product Type
7.4.4.2. RoW Immunohistochemistry (IHC) Market, by Application
7.4.4.3. RoW Immunohistochemistry (IHC) Market, by End User
7.4.4.4. RoW Immunohistochemistry (IHC) Market, by Region
7.4.4.4.1. Middle East
7.4.4.4.2. Africa
7.4.4.4.3. South America
8. Immunohistochemistry (IHC) Global Company Share Analysis – Key 3-5 Companies
9. Immunohistochemistry (IHC) Company and Product Profiles
9.1. F. Hoffmann-La Roche Ltd
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4. Product Listing
9.1.5. Entropy
9.2. Agilent Technologies, Inc.
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4. Product Listing
9.2.5. Entropy
9.3. Bio-Rad Laboratories, Inc.
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4. Product Listing
9.3.5. Entropy
9.4. Thermo Fisher Scientific
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4. Product Listing
9.4.5. Entropy
9.5. PerkinElmer Inc
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4. Product Listing
9.5.5. Entropy
9.6. Danaher Corporation
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4. Product Listing
9.6.5. Entropy
9.7. Merck KGaA
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4. Product Listing
9.7.5. Entropy
9.8. Bio-Techne
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4. Product Listing
9.8.5. Entropy
9.9. Genemed Biotechnologies, Inc
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4. Product Listing
9.9.5. Entropy
9.10. Abcam plc
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4. Product Listing
9.10.5. Entropy
9.11. Becton, Dickinson and Company
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4. Product Listing
9.11.5. Entropy
9.12. Bio SB, Inc
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4. Product Listing
9.12.5. Entropy
9.13. BioGenex
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4. Product Listing
9.13.5. Entropy
9.14. Biocare Medical, LLC
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4. Product Listing
9.14.5. Entropy
9.15. Diagnostic BioSystems Inc
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4. Product Listing
9.15.5. Entropy
9.16. ROCKLAND IMMUNOCHEMICALS, INC
9.16.1. Company Overview
9.16.2. Company Snapshot
9.16.3. Financial Overview
9.16.4. Product Listing
9.16.5. Entropy
9.17. Elabscience Biotechnology Inc
9.17.1. Company Overview
9.17.2. Company Snapshot
9.17.3. Financial Overview
9.17.4. Product Listing
9.17.5. Entropy
9.18. Sakura Finetek USA, Inc
9.18.1. Company Overview
9.18.2. Company Snapshot
9.18.3. Financial Overview
9.18.4. Product Listing
9.18.5. Entropy
9.19. CANDOR Bioscience GmbH
9.19.1. Company Overview
9.19.2. Company Snapshot
9.19.3. Financial Overview
9.19.4. Product Listing
9.19.5. Entropy
9.20. NeoGenomics Laboratories
9.20.1. Company Overview
9.20.2. Company Snapshot
9.20.3. Financial Overview
9.20.4. Product Listing
9.20.5. Entropy
10. KOL Views
11. Project Approach
12. About DelveInsight
13. Disclaimer & Contact Us
